The study will be a cross-sectional study with ARV drug levels (Cmin and Cmax) measured weekly for three weeks Three samples will be taken from each subject to reduce variability due to both technologic and biologic sources. Data will be collected on demographic characteristics, clinical disease and ARV history and on clinical toxicities at the first visit. Blood work will be carried out on the first visit to assess for laboratory toxicity and hormonal levels.